PDE-5 inhibitor, Vardenafil, increases circulating progenitor cells in humans

Int J Impot Res. 2005 Jul-Aug;17(4):377-80. doi: 10.1038/sj.ijir.3901325.

Abstract

Bone marrow-derived endothelial progenitor cells (EPCs) originate from haematopoietic stem cells in bone marrow and migrate into the peripheral circulation to promote endothelial repair and neovascularization. The number of circulating progenitor cells is reduced in patients with cardiovascular risk factor. The aim of our study was to determine the number of these cells in healthy patients and to evaluate the effect of Vardenfil, a phosphodiesterases-5 (PDE-5) inhibitor, in the number of circulating EPCs. In our study, we found a significant increase in the number of these cells after the drug administration.

Publication types

  • Clinical Trial

MeSH terms

  • 3',5'-Cyclic-GMP Phosphodiesterases / antagonists & inhibitors*
  • Adult
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • Endothelium, Vascular / cytology
  • Flow Cytometry
  • Hematopoietic Stem Cell Mobilization*
  • Hematopoietic Stem Cells / cytology
  • Hematopoietic Stem Cells / drug effects*
  • Humans
  • Imidazoles / administration & dosage*
  • Male
  • Phosphodiesterase Inhibitors / administration & dosage*
  • Piperazines / administration & dosage*
  • Sulfones / administration & dosage
  • Triazines / administration & dosage
  • Vardenafil Dihydrochloride

Substances

  • Imidazoles
  • Phosphodiesterase Inhibitors
  • Piperazines
  • Sulfones
  • Triazines
  • Vardenafil Dihydrochloride
  • 3',5'-Cyclic-GMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • PDE5A protein, human